2025 FDA-AACR Workshop: DPD Deficiency and Weighing Potential Harms
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with fluoropyrimidines.
Related Articles
FDA Approves Tislelizumab Plus Chemo for PD-L1+ Unresectable or Metastatic Gastric/GEJ Cancer
The FDA has approved tislelizumab plus chemotherapy for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Diet Quality, Dietary Inflammatory Potential, and Risk of Prostate Cancer Grade Reclassification
This cohort study examines whether there is an association of diet quality and dietary inflammatory potential with prostate cancer grade reclassification in men with grade…
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study
The negative patient-reported effects associated with a CSD result from MCED testing were small and returned to baseline within 12 months for participants with or…
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
PURPOSEIn patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab…
National Fellows Forum Highlights Future Research Directions in HGSOC and HCC
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OCE Conversations on Cancer – Cervical Cancer Treatment Innovation: A Collaborative Discussion
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Belantamab mafodotin combination therapies in early RRMM
During the Multiple Myeloma Hub Steering Committee Meeting in November 2024, key opinion leaders met to discuss belantamab mafodotin combination therapies in early RRMM, with…
Investigating higher teclistamab step-up dosing in R/R myeloma: results from MajesTEC-1
Jeffrey Matous, MD, Colorado Blood Cancer Institute, Denver, CO, comments on the potential benefits of using alternative teclistamab step-up dosing strategies in patients with relapsed/refractory…
Uncovering the Power of Introspection to Drive Personalized Cancer Care
A series of events took John L. Marshall, MD, down his path of becoming a gastrointestinal oncology leader, with a drive that has also solidified…